CareersPipelineCollaboration RareInnovation SVGOMG The best SVG optimizer and minifier Open SVG Paste markup Demo Contribute SVGOMG provides you several options to clean and compress your SVG files. Clean up, remove, merge, minify. Upload or copy the source of your SVG to get started! 947 bytes → 267 bytes 28.19% Finance peopleAdvance treatment Skip to main contentSkip to navigationSkip to search
HNSA   ( ,  %) SEK
Quotes are delayed 15 minutes
Hansa Biopharma

Virtual Investor Event

Autoimmune Deep Dive
Guillain-Barré Syndrome 

Join Hansa Biopharma for an investor event featuring KOLs David R. Cornblath, MD (Johns Hopkins University), and Simon Rinaldi, MRCP(Neuro), PhD (University of Oxford), who will discuss the unmet need and current treatment landscape for Guillain-Barré syndrome (GBS), an acute, rare, paralyzing inflammatory disease of the peripheral nervous system.

16 June 2025, 14:00 CEST / 8:00 AM ET

Register and attend
Event

Investors

OMX Stockholm

( %)
HNSA  SEK

The share

Some content on this page is only available in English. All material required under applicable law, regulation or code is available in English and Swedish.

Antibodies
Latest Financial Results

Interim report January-March 2025

Press release Report Presentation Webcast Transcript
View all results
Calendar

Upcoming events

04
Jun

Annual General Meeting 2025

16
Jun

Autoimmune Deep Dive - Guillain-Barré Syndrome

17
Jul

Half-year Report for January-June 2025

View all events

Press releases

Our latest press releases

Read all news

Hansa Biopharma Reports First Quarter and Interim January-March 2025 Financial Results

Regulatory press release

24/04/2025
Hansa Biopharma appoints new Chief Executive Officer

Regulatory press release

24/04/2025
Hansa Biopharma to host Q1 2025 interim results conference call

03/04/2025
Hansa Biopharma to attend Van Lanschot Kempen Life Sciences Conference

25/03/2025
Virtual Investor Event

Autoimmune Deep Dive Guillain-Barré Syndrome

Join Hansa Biopharma for an investor event featuring KOLs David R. Cornblath, MD (Johns Hopkins University), and Simon Rinaldi, MRCP(Neuro), PhD (University of Oxford), who will discuss the unmet need and current treatment landscape for Guillain-Barré syndrome (GBS), an acute, rare, paralyzing inflammatory disease of the peripheral nervous system.

Monday, June 16, 2025 | 14:00 CEST / 8:00 AM ET
Live Webcast

Register and attend

Hansa Biopharma in brief

Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life altering treatments for patients with rare immunological conditions.

Page: /

Hansa Biopharma Q1 2025 Presentation

View presentation

Annual Report 2024
Sustainability Report 2024

Science-led
Patient first
Values driven

Read the reports

Upcoming

Key progress and look ahead

 Progress to dateNext anticipated milestone
AUTOIMMUNE

TRIAL COMPLETED: 15-MedIdeS-09 (GBS) Ph 2 trial and data contextualization

ENROLLMENT COMPLETED: GOOD-IDES-2 Ph 3 (anti-GBM) trial

COMPLETED: NICE-01 Ph 1 study of HNSA-5487 with data on exploratory endpoints and clinical development path selected

15-MedIdeS-09 Ph 2 (GBS) Publication in peer-reviewed journal

Preparation of Ph 3 trial in GBS

GOOD-IDES-2 Ph 3 (anti-GBM) data readout in 2025

HNSA-5487: Alignment with regulatory authorities on clinical development pathway in neuro-autoimmune diseases

GENE THERAPY

STUDY INITIATED: SRP 9001-104 Ph 1 study (DMD) - Sarepta

STUDY INITIATED: GNT-018-IDES Ph 2 study (Crigler-Najjar) - Genethon

AskBio (Pompe) preclinical

SRP 9001-104 Ph 1 study (DMD) completion of enrollment

GNT-018-IDES study (Crigler-Najjar) completion of enrollment

TRANSPLANTATION

FULL RANDOMIZATION: ConfIdeS Ph 3 trial

DATA PUBLISHED: 15-HMedIdeS-14 data publication in peer reviewed journal

ConfIdeS Ph 3 12 month follow up and BLA submission in 2H 2025

Post Approval Efficacy Study (PAES) readout

Focus areas Pipeline
Investor relations

Evan Ballantyne

Chief Financial Officer

Email: [email protected]

E-mail

Sign up to receive the latest updates

Choose type

I consent to Hansa Biopharma handling my personal data. See our Privacy Policy for information about how we handle personal data.

Thank you. You will get an e-mail message to activate your subscription.